Pharmacokinetics, biodistribution and antitumour effects of <i>Sclerotium rolfsii</i> lectin in mice

Anupama, S, Laha, Preeti, Sharma, Mamta, Pathak, Kamal, Bane, Sanjay, Ingle, Arvind D, Gota, Vikram, Kalraiya, Rajiv D, Yu, Lu-Gang ORCID: 0000-0001-9641-3712, Rhodes, Jonathan M ORCID: 0000-0002-1302-260X
et al (show 2 more authors) (2017) Pharmacokinetics, biodistribution and antitumour effects of <i>Sclerotium rolfsii</i> lectin in mice. ONCOLOGY REPORTS, 37 (5). pp. 2803-2810.

[img] Text
2017-Oncol Rep Vol37 No5 Pg2803 (002).pdf - Published version

Download (670kB)


Sclerotium rolfsii lectin (SRL) is a lectin isolated from the fungus Sclerotium rolfsii and has exquisite binding specificity towards the oncofetal Thomsen-Friedenreich antigen (TF-Ag; Galβ1-3GalNAcα-O-Ser/Thr) and its derivatives. Previous studies have shown that SRL inhibits the proliferation of human colon, breast and ovarian cancer cells in vitro and suppresses tumour growth in mice when introduced intratumourally. The present study assessed the effect of SRL on tumour growth when introduced intraperitoneally in BALB/c nude mice and investigated the pharmacokinetics and biodistribution of SRL in Swiss albino mice. When 9 doses of SRL (30 mg/kg body weight/mice) was administered to BALB/c nude mice bearing human colon cancer HT-29 xenografts, a substantial reduction in tumour size was observed. A 35.8% reduction in tumour size was noted in the treated animals after 17 days. SRL treatment also inhibited angiogenesis, and the tumours from the treated animals were observed to carry fewer blood vessels and express less angiogenesis marker protein CD31, than that from the control animals. Pharmacokinetics and biodistribution analysis revealed that SRL was detected in the serum after 1 h and its level peaked after 24 h. SRL was not detected in any of the organs apart from the kidney where a trace amount was detected after 24 h of SRL injection. No significant changes were observed in any of the biochemical parameters tested including SGOT, SGPT, LDH, CREAT and BUN in the SRL-treated mice compared to these levels in the controls. This suggests that SRL has good potential to be developed as a therapeutic agent for cancer treatment and warrant further investigations in vivo and subsequent clinical trials.

Item Type: Article
Uncontrolled Keywords: pharmacokinetics, biodistribution, Sclerotium rolfsii lectin, tumour regression, anti-angiogenesis
Depositing User: Symplectic Admin
Date Deposited: 29 Aug 2017 15:52
Last Modified: 12 Oct 2023 07:02
DOI: 10.3892/or.2017.5545
Related URLs: